• Clinical trials research networks
    Dr. Kennedy has developed Neurobiology and Psychopharmacology units at the Centre for Addiction and Mental Health and University Health Network. More recently, he has worked with researchers across Canada (as Principal Investigator) to develop the Canadian Biomarker Integration Network in Depression (CAN-BIND), a clinical trials network focused on standardized measurement and analysis of biomarkers, and funded by the Ontario Brain Institute and the Canadian Institutes of Health Research, together with private sector partnerships and individual donors.
  • Biomarkers of treatment response
    His research focuses on identifying biomarkers of illness and treatment response in Major Depressive Disorder (MDD), using extensive clinical, neuroimaging, neurophysiological and molecular profiling, together with an integrative bioinformatics platform. This project is part of the CAN-BIND program.
  • Neuroimaging and neurostimulation
    Research interest in neuroimaging and neurostimulation has progressed from investigational Positron Emission Tomography (PET) work at the Vivian Rakoff Centre, University of Toronto, exploring regional brain changes following antidepressant pharmacotherapy and psychotherapy to deep brain stimulation targeting the subcallosal cingulated gyrus in treatment resistant depression in collaboration with Dr. Andres Lozano (Neurosurgery), Dr. Peter Giacobbe (Psychiatry) and Dr. Helen Mayberg (Neurology and Psychiatry, Emory University). This has been extended to include structural and functional MRI studies to complement this work and the biomarker work (in collaboration with Dr. Jonathan Downar, Psychiatry).
  • Scale development and predictors of outcome
    The Toronto Antidepressant Side Effect Scale (TASES), the Sexual Side Effects (SexFx) Scale and the 7-Item Hamilton Depression Scale (HAMD-7) have been developed in collaboration with Drs. Roger McIntyre and Michael Bagby. In addition, measurement of personality dimension in relation to depression, response to antidepressants and treatment selection have been research foci. The Depression Inventory Development (DID) is part of the CAN-BIND platform.
  • Guideline development and health policy
    Dr. Kennedy is the founding Chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT), an organization linking mental health professionals across Canada. Guidelines and regular updates for the treatment of Major Depressive Disorder (MDD) and Bipolar Disorder (BD) have been published nationally and internationally. The ongoing work of CANMAT in providing education for the public, health care providers, policy developers and others, plays a large role in the knowledge translation component of the CAN-BIND network.
Gen Hosp Psychiatry. 2019 May 10;:
McInerney SJ, Fallahi A, Edgar NE, Ceniti AK, Rizvi SJ, Beder M, Bergmans Y, Kennedy SH
Syst Rev. 2019 May 15;8(1):115
Espinet S, Corrin T, Baliunas D, Quilty L, Zawertailo L, Rizvi SJ, deRuiter W, Bonato S, De Luca V, Kennedy S, Selby P
J Clin Psychiatry. 2019 May 07;80(3):
Belzeaux R, Fiori LM, Lopez JP, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW, Leri F, MacQueen GM, Milev R, Müller DJ, Parikh SV, Rotzinger S, Soares CN, Uher R, Foster JA, Kennedy SH, Turecki G
Neuroimage. 2019 May 07;197:589-597
Nogovitsyn N, Souza R, Muller M, Srajer A, Hassel S, Arnott SR, Davis AD, Hall GB, Harris JK, Zamyadi M, Metzak PD, Ismail Z, Bray SL, Lebel C, Addington JM, Milev R, Harkness KL, Frey BN, Lam RW, Strother SC, Goldstein BI, Rotzinger S, Kennedy SH,...
World Psychiatry. 2019 Jun;18(2):183-191
Boschloo L, Bekhuis E, Weitz ES, Reijnders M, DeRubeis RJ, Dimidjian S, Dunner DL, Dunlop BW, Hegerl U, Hollon SD, Jarrett RB, Kennedy SH, Miranda J, Mohr DC, Simons AD, Parker G, Petrak F, Herpertz S, Quilty LC, John Rush A, Segal ZV, Vittengl JR,...
World J Biol Psychiatry. 2019 Mar 25;:1-12
Andreazza AC, Laksono I, Fernandes BS, Toben C, Lewczuk P, Riederer P, Kennedy SH, Kapogiannis D, Thibaut F, Gerlach M, Gallo C, Kim YK, Grünblatt E, Yatham L, Berk M, Baune BT
J Clin Psychiatry. 2019 Feb 05;80(2):
Kennedy SH, Lam RW, Rotzinger S, Milev RV, Blier P, Downar J, Evans KR, Farzan F, Foster JA, Frey BN, Giacobbe P, Hall GB, Harkness KL, Hassel S, Ismail Z, Leri F, McInerney S, MacQueen GM, Minuzzi L, Müller DJ, Parikh SV, Placenza FM, Quilty LC,...
J Psychiatry Neurosci. 2019 Mar 06;44(3):1-14
MacQueen GM, Hassel S, Arnott SR, Jean A, Bowie CR, Bray SL, Davis AD, Downar J, Foster JA, Frey BN, Goldstein BI, Hall GB, Harkness KL, Harris J, Lam RW, Lebel C, Milev R, Müller DJ, Parikh SV, Rizvi S, Rotzinger S, Sharma GB, Soares CN, Turecki G,...
Am J Psychiatry. 2019 Feb 15;:appiajp201818091096
Kaster TS, Downar J, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, Knyahnytska Y, Kennedy SH, Lam RW, Daskalakis ZJ, Blumberger DM
Aust N Z J Psychiatry. 2019 Feb 13;:4867419829228
Slyepchenko A, Allega OR, Leng X, Minuzzi L, Eltayebani MM, Skelly M, Sassi RB, Soares CN, Kennedy SH, Frey BN

Pages


 

Professor, Department of Psychiatry, University of Toronto
Professor, Institute of Medical Science, University of Toronto
Principal Investigator, Canadian Biomarker Integration Network for Depression (CAN-BIND)